NTRK1 and glioblastoma: Currently, several small molecule inhibitors have been extensively tested in GBM patients, mainly targeting the major dysregulated pathways in GBM, including receptor tyrosine kinases, the PI3K/AKT/mTOR pathway, the p53 pathway, and the RB pathway.[144]